Ignite Creation Date:
2025-12-24 @ 6:56 PM
Ignite Modification Date:
2026-03-02 @ 7:00 AM
Study NCT ID:
NCT04631757
Status:
UNKNOWN
Last Update Posted:
2020-11-17
First Post:
2020-11-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
MA-GC-II-006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |